

Press release

Stockholm, Sweden, 11 February 2026

Sobi to host a Capital Markets Day on 18 February 2026

Swedish Orphan Biovitrum AB (Sobi) invites investors, analysts, and other stakeholders to its upcoming Capital Markets Day (CMD), which will be held in person in Stockholm, Sweden, on **18 February 2026**, starting at 13:00 CET. A live webcast will also be available for remote participants.

The CMD will feature presentations by Guido Oelkers, CEO, and members of the Management Team. Participants will have the opportunity to hear updates on Sobi's strategy and physician-led therapeutic area sessions, followed by a Q&A session. The CMD is expected to conclude at approximately 16:00 CET.

- Pre-registration for attendance: [click here](#) (note pre-registration is required for onsite attendance.)

This event provides an excellent opportunity for stakeholders gain insights into the company's strategic direction ahead.

Agenda in brief:

- Guido Oelkers – CEO Sobi. Ambition 2030
- Lydia Abad-Franch – CMO Sobi. Pipeline and innovation at Sobi
- Robert Keenan – CMO Arthrosi. Disease Deep Dive: The painful burden of severe gout
- Duane Barnes, Sofiane Fahmy, Norbert Oppitz – Roundtable with Regional Heads
- Professor Klaus Parhofer – Disease Deep Dive: The silent risk of sHTG
- Professor Evangelos Giannarellis – Disease Deep dive: Precision medicine in sepsis
- Henrik Stenqvist – CFO Sobi. Delivering Shareholder Value
- Guido Oelkers – CEO Sobi. Wrap up and Q&A

Sobi

Sobi® is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases. Sobi has approximately 1,900 employees across Europe, North America, the Middle East, Asia and Australia. In 2025, revenue amounted to SEK 28 billion. Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at [sobi.com](#) and [LinkedIn](#).

Contacts

For details on how to contact the Sobi Investor Relations Team, please [click here](#). For Sobi Media contacts, [click here](#).

Gerard Tobin
Head of Investor Relations